On this page
Gaucher disease type 1
This leads to an accumulation of this substance in certain cells, primarily in the spleen, liver, and bone marrow. It can cause a range of symptoms, including anaemia, bone problems, and an enlarged spleen and liver.
Available at Jeen Health
Clinical tests that include this
Overview
Gaucher disease type 1 is a type of lysosomal storage disorder, a group of conditions caused by problems with lysosomes. Lysosomes are often called the 'recycling centres' of the cell because they contain enzymes that break down waste products. In Gaucher disease type 1, there is a deficiency in the enzyme glucocerebrosidase, which is essential for breaking down a specific type of fatty molecule called glucocerebroside [PMID:33676778]. Without enough of this enzyme, glucocerebroside builds up in cells, particularly in macrophages (a type of white blood cell). These 'Gaucher cells' then accumulate in organs, leading to the various signs and symptoms of the condition.
Gaucher disease is categorised into three main types based on the presence and severity of neurological involvement. Type 1, the most common form, typically does not affect the brain and spinal cord, although some neurological symptoms can occur in rare cases. Types 2 and 3 involve the central nervous system more significantly. Type 1 is a chronic condition, meaning it is long-lasting, and its severity can vary considerably among affected individuals. It is estimated to affect between 1 in 40,000 and 1 in 60,000 people in the general population.
Symptoms & clinical features
The symptoms of Gaucher disease type 1 can appear at any age, from childhood to adulthood, and their severity can differ greatly between individuals. Common symptoms are often related to the build-up of glucocerebroside in certain organs, especially the spleen, liver, and bones [PMID:33676778]. Many people with type 1 Gaucher disease experience an enlarged spleen (splenomegaly) and liver (hepatomegaly), which may cause discomfort or a feeling of fullness in the abdomen. An enlarged spleen can also lead to a reduction in healthy blood cells.
Bone-related issues are frequent, ranging from bone pain and joint pain to more severe complications like bone crises (sudden, intense bone pain) or increased risk of fractures. Some individuals may develop osteopenia (reduced bone density) or osteoporosis (fragile bones) [PMID:33676778]. Blood abnormalities are also common, including anaemia (low red blood cell count), which can cause fatigue and weakness, and thrombocytopenia (low platelet count), which may lead to easy bruising or bleeding. Less commonly, lung involvement and certain kidney problems have been observed. The progressive nature of the condition means that symptoms can worsen over time if not managed.
Video: Genetics 101
Affected organs
Gaucher disease type 1 primarily affects several key organ systems due to the accumulation of glucocerebroside within macrophage cells. The spleen and liver are commonly impacted, leading to their enlargement. An enlarged spleen can sequester blood cells, causing low blood counts, while an enlarged liver may affect its normal function.
The skeletal system is another major site of involvement. Bone marrow can be infiltrated by Gaucher cells, leading to bone pain, reduced bone density, and a higher risk of fractures. The joints may also be affected, causing discomfort and limiting mobility. Additionally, bone crises, characterised by severe pain, can occur. Although less common in type 1, other organs such as the lungs and, in rare instances, the kidneys can also show signs of involvement.
Risks & severity
Gaucher disease type 1 presents with a wide spectrum of severity, even within the same family. Some individuals may have very mild symptoms that go undiagnosed for many years, while others experience significant health challenges from a young age. The condition is chronic and progressive, meaning symptoms can worsen over time if appropriate management is not in place.
Complications such as significant bone damage, including avascular necrosis (bone tissue death due to lack of blood supply), can occur. Individuals with Gaucher disease type 1 may also have an increased risk of certain other conditions, although this is still an area of ongoing research. Life expectancy for individuals with type 1 is generally thought to be near normal with effective treatment. The age of symptom onset is variable, ranging from childhood to late adulthood, highlighting the diverse clinical presentation of this condition.
Genetic causes
Gaucher disease type 1 is caused by pathogenic variants in the GBA gene. This gene provides instructions for making an enzyme called glucosylceramidase beta 1, also known as acid beta-glucosidase. This enzyme is located in lysosomes, which are small compartments within cells responsible for breaking down and recycling various waste products. The glucosylceramidase beta 1 enzyme's specific role is to break down glucocerebroside, a fatty substance, into simpler components.
When there are pathogenic variants in the GBA gene, the enzyme is either not produced in sufficient amounts or does not function correctly. This leads to an accumulation of glucocerebroside within the lysosomes of certain cells, particularly macrophages. These lipid-laden macrophages, known as Gaucher cells, then build up in organs such as the spleen, liver, and bone marrow, causing the characteristic signs and symptoms of Gaucher disease type 1.
- GBA glucosylceramidase beta 1The GBA gene provides instructions for producing the lysosomal acid glucosylceramidase enzyme, crucial for breaking down a fatty molecule called glucocerebroside within cells.
Inheritance pattern
Gaucher disease type 1 is inherited in an autosomal recessive pattern. This means that an individual must inherit two altered copies of the GBA gene, one from each parent, to develop the condition. If a person inherits only one altered copy of the GBA gene, they are considered a 'carrier.' Carriers typically do not show symptoms of Gaucher disease because their single working copy of the gene produces enough of the enzyme for normal function.
When two carriers have children, there is a 25% chance with each pregnancy that the child will inherit two altered copies of the gene and therefore develop Gaucher disease. There is a 50% chance the child will be a carrier, and a 25% chance the child will inherit two working copies of the gene and not be affected or a carrier. Genetic counselling is available for families to understand these inheritance patterns and the implications for family planning.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosing Gaucher disease type 1 typically begins with a clinical suspicion based on the presence of characteristic symptoms like an enlarged spleen or liver, anaemia, or unexplained bone pain. Initial diagnostic investigations may include blood tests to check for low blood counts and liver function.
A definitive diagnosis is usually confirmed through a specific enzyme assay, which measures the activity of the glucocerebrosidase enzyme in white blood cells or cultured skin fibroblasts. Reduced enzyme activity indicates Gaucher disease. Genetic testing of the GBA gene can then be performed to identify the specific pathogenic variants, which helps confirm the diagnosis and distinguish between Gaucher disease types. This genetic testing falls under the NHS National Genomic Test Directory R-codes and is usually requested by a specialist clinician, such as a haematologist, gastroenterologist, or a clinical genetics team. Referral to clinical genetics services or genetic counselling is often recommended to discuss the implications of the diagnosis and inheritance for the individual and their family.
Management & lifestyle
Management for Gaucher disease type 1 is primarily aimed at reducing symptoms, preventing complications, and improving quality of life. The main treatment is enzyme replacement therapy (ERT), where the deficient enzyme is replaced by regular intravenous infusions of a synthetic version [PMID:24072978]. ERT helps to clear the accumulated glucocerebroside from affected organs, which can reduce spleen and liver size, improve blood counts, and alleviate bone pain. Some individuals may also be candidates for substrate reduction therapy (SRT), which involves taking medication orally to reduce the amount of glucocerebroside the body produces.
Regular monitoring is crucial to assess the effectiveness of treatment and to detect any emerging complications. This typically involves periodic blood tests, bone density scans, and imaging of the spleen and liver. Management is usually overseen by a multidisciplinary team of specialists, including haematologists, hepatologists, orthopaedic specialists, and geneticists. Lifestyle considerations, such as maintaining a healthy diet and engaging in appropriate exercise, are also important. Individuals are encouraged to work closely with their healthcare team to develop a personalised management plan within the NHS framework.
UK care pathway
In the UK, individuals suspected of having Gaucher disease type 1 will typically be referred through their GP or specialist to a clinical genetics service or another relevant specialist, such as a haematologist or metabolic specialist. The NHS Genomic Medicine Service provides comprehensive pathways for diagnosis and management of rare genetic conditions. Diagnostic genetic testing for Gaucher disease falls within the NHS National Genomic Test Directory, covered by specific R-codes for lysosomal storage disorders.
If a diagnosis is confirmed, care is generally coordinated by a specialist metabolic centre, often in conjunction with a regional clinical genetics service. These centres provide access to enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) where appropriate. Genetic counsellors play a vital role in supporting individuals and families, explaining the inheritance pattern, discussing family planning options, and providing emotional support and information.
Frequently asked questions
What is the difference between Gaucher disease type 1 and other types?
Gaucher disease is categorised into three main types. Type 1 is the most common and generally does not involve the brain or spinal cord. Types 2 and 3 are rarer and include neurological symptoms, with Type 2 being the most severe and rapidly progressing form.
Is Gaucher disease type 1 curable?
Currently, there is no cure for Gaucher disease type 1, but effective treatments are available to manage the symptoms and prevent complications. These treatments, such as enzyme replacement therapy (ERT) and substrate reduction therapy (SRT), can significantly improve the quality of life for affected individuals.
How is Gaucher disease type 1 inherited?
Gaucher disease type 1 is inherited in an autosomal recessive manner. This means both parents must be carriers of a pathogenic GBA gene variant, and the child must inherit two altered copies (one from each parent) to develop the condition. Carriers typically do not have symptoms.
What are the common treatments for Gaucher disease type 1?
The primary treatments are enzyme replacement therapy (ERT), given intravenously, and substrate reduction therapy (SRT), taken orally. These therapies aim to either replace the missing enzyme or reduce the production of the fatty substance that accumulates in the body.
Can Gaucher disease type 1 affect my children?
If you have Gaucher disease type 1, your children will inherit one altered copy of the GBA gene from you. If your partner is also a carrier or has Gaucher disease, there is a risk that your children could inherit two altered copies and develop the condition. Genetic counselling can provide personalised risk assessments and guidance.
References
- Stone WL, Mukkamalla SKR, Master SR. Gaucher Disease. 2023. PMID: 28846219
- Nagral A. Gaucher disease. Journal of clinical and experimental hepatology. 2014. PMID: 25755533
- Weinreb NJ, Aggio MC, Andersson HC. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Seminars in hematology. 2004. PMID: 15468046
- Shayman JA, Hinkovska-Galcheva V, Shu L. Inhibitors of Glucosylceramide Synthase. Methods in molecular biology (Clifton, N.J.). 2023. PMID: 36587085
- Kałużna M, Trzeciak I, Ziemnicka K. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet journal of rare diseases. 2019. PMID: 31791361
- Utz J, Whitley CB, van Giersbergen PL. Comorbidities and pharmacotherapies in patients with Gaucher disease type 1: The potential for drug-drug interactions. Molecular genetics and metabolism. 2016. PMID: 26674302
- Scott LJ. Eliglustat: A Review in Gaucher Disease Type 1. Drugs. 2015. PMID: 26384672
- Pratt VM, Scott SA, Pirmohamed M. Eliglustat Therapy and CYP2D6 Genotype. 2012. PMID: 33351401